Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Mazindol · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Mazindol | DRUG | - |
Please contact site for information.
Mazindol is a small molecule being investigated for the treatment of cocaine-related disorders. It is currently in Phase 2 clinical development as an investigational therapy for this condition.
Mazindol is being developed by National Healthcare Corp. (NHC). The company is conducting clinical research to evaluate the drug for cocaine-related disorders.
Mazindol is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities for any use.
Mazindol has one completed clinical trial, NCT00000277, which was a Phase 2 study conducted in the United States. The trial evaluated Mazindol for cocaine-related disorders in adults.
Mazindol is not FDA approved. It is an investigational drug currently in Phase 2 clinical development for cocaine-related disorders, and its safety and efficacy have not been established.